A robust xenotransplantation model for acute myeloid leukemia.

Abstract:

:Xenotransplantation of human acute myeloid leukemia (AML) in immunocompromised animals has been critical for defining leukemic stem cells. However, existing immunodeficient strains of mice have short life spans and low levels of AML cell engraftment, hindering long-term evaluation of primary human AML biology. A recent study suggested that NOD/LtSz-scid IL2Rgammac null (NSG) mice have enhanced AML cell engraftment, but this relied on technically challenging neonatal injections. Here, we performed extensive analysis of AML engraftment in adult NSG mice using tail vein injection. Of the 35 AML samples analyzed, 66% showed bone marrow engraftment over 0.1%. Further, 37% showed high levels of engraftment (>10%), with some as high as 95%. A 2-44-fold expansion of AML cells was often seen. Secondary and tertiary recipients showed consistent engraftment, with most showing further AML cell expansion. Engraftment did not correlate with French-American-British subtype or cytogenetic abnormalities. However, samples with FLT3 mutations showed a higher probability of engraftment than FLT3 wild type. Importantly, animals developed organomegaly and a wasting illness consistent with advanced leukemia. We conclude that the NSG xenotransplantation model is a robust model for human AML cell engraftment, which will allow better characterization of AML biology and testing of new therapies.

journal_name

Leukemia

journal_title

Leukemia

authors

Sanchez PV,Perry RL,Sarry JE,Perl AE,Murphy K,Swider CR,Bagg A,Choi JK,Biegel JA,Danet-Desnoyers G,Carroll M

doi

10.1038/leu.2009.143

subject

Has Abstract

pub_date

2009-11-01 00:00:00

pages

2109-17

issue

11

eissn

0887-6924

issn

1476-5551

pii

leu2009143

journal_volume

23

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • The molecular characterization and clinical management of multiple myeloma in the post-genome era.

    abstract::Cancer-causing mutations disrupt coordinated, precise programs of gene expression that govern cell growth and differentiation. Microarray-based gene-expression profiling (GEP) is a powerful tool to globally analyze these changes to study cancer biology and clinical behavior. Despite overwhelming genomic chaos in multi...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/leu.2009.160

    authors: Zhou Y,Barlogie B,Shaughnessy JD Jr

    更新日期:2009-11-01 00:00:00

  • Expression of the monocyte-specific esterase gene in leukemia-lymphoma cell lines.

    abstract::The expression of the monocyte esterase was examined in a panel of 77 continuous human leukemia-lymphoma cell lines representing all hematopoietic cell lineages and in 16 other cell lines. Accumulation of mRNA, determined by Northern blotting with the cDNA probe HMSE-1, and production of the protein, shown by isoelect...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Uphoff CC,Gignac SM,Metge K,Zschunke F,Radzun HJ,Drexler HG

    更新日期:1993-01-01 00:00:00

  • Leukemic dendritic cells generated in the presence of FLT3 ligand have the capacity to stimulate an autologous leukemia-specific cytotoxic T cell response from patients with acute myeloid leukemia.

    abstract::It has been proposed that adoptive immunotherapy, for the treatment of relapsed AML, with cytotoxic T lymphocytes which show a relative specificity for the leukemic cells may have the advantage of maximizing the beneficial anti-leukemic effect whilst minimizing the probability of graft-versus-host disease. In this stu...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402013

    authors: Woiciechowsky A,Regn S,Kolb HJ,Roskrow M

    更新日期:2001-02-01 00:00:00

  • Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group.

    abstract::The current study was initiated to compare the anti-lymphoma activity and side-effects of prednimustine/mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) in patients with advanced low-grade non-Hodgkin's lymphomas in way of a prospective randomized multicenter trial. Two hundred and forty-six patie...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Unterhalt M,Herrmann R,Tiemann M,Parwaresch R,Stein H,Trümper L,Nahler M,Reuss-Borst M,Tirier C,Neubauer A,Freund M,Kreuser ED,Dietzfelbinger H,Bodenstein H,Engert A,Stauder R,Eimermacher H,Landys K,Hiddemann W

    更新日期:1996-05-01 00:00:00

  • Is t(14;18)(q32;q21) a constant finding in follicular lymphoma? An interphase FISH study on 63 patients.

    abstract::The translocation (14;18)(q32;q21) is the hallmark of follicular lymphoma (FL). However, conventional cytogenetics and PCR techniques fail to detect it in at least 10% of cases. In order to evaluate the true incidence of this translocation in FL, we analyzed 63 patients with FL, and 17 patients with diffuse large cell...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402739

    authors: Godon A,Moreau A,Talmant P,Baranger-Papot L,Geneviève F,Milpied N,Zandecki M,Avet-Loiseau H

    更新日期:2003-01-01 00:00:00

  • Relation between genetic variants of the ataxia telangiectasia-mutated (ATM) gene, drug resistance, clinical outcome and predisposition to childhood T-lineage acute lymphoblastic leukaemia.

    abstract::The T-lineage phenotype in children with acute lymphoblastic leukaemia (ALL) is associated with in vitro drug resistance and a higher relapse-risk compared to a precursor B phenotype. Our study was aimed to investigate whether mutations in the ATM gene occur in childhood T-lineage acute lymphoblastic leukaemia (T-ALL)...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403943

    authors: Meier M,den Boer ML,Hall AG,Irving JA,Passier M,Minto L,van Wering ER,Janka-Schaub GE,Pieters R

    更新日期:2005-11-01 00:00:00

  • The JAK2V617F-bearing vascular niche promotes clonal expansion in myeloproliferative neoplasms.

    abstract::The acquired kinase mutation JAK2V617F plays a central role in myeloproliferative neoplasms (MPNs). However, the mechanisms responsible for the malignant hematopoietic stem/progenitor cell (HSPC) expansion seen in patients with MPNs are not fully understood, limiting the effectiveness of current treatment. Endothelial...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2017.233

    authors: Zhan H,Lin CHS,Segal Y,Kaushansky K

    更新日期:2018-02-01 00:00:00

  • A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group.

    abstract::A widely accepted definition of resistance or intolerance to hydroxyurea (HU) in patients with essential thrombocythemia (ET) is lacking. An international working group (WG) was convened to develop a consensus formulation of clinically significant criteria for defining resistance/intolerance to HU in ET. To this aim, ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404473

    authors: Barosi G,Besses C,Birgegard G,Briere J,Cervantes F,Finazzi G,Gisslinger H,Griesshammer M,Gugliotta L,Harrison C,Hasselbalch H,Lengfelder E,Reilly JT,Michiels JJ,Barbui T

    更新日期:2007-02-01 00:00:00

  • Prognostic relevance of the expression of Tdt and CD7 in 335 cases of acute myeloid leukemia.

    abstract::We have analyzed the expression of Tdt and CD7 in 335 cases of unequivocal acute myeloid leukemia (AML). Tdt was expressed in 80 (25%) of 321 evaluable cases. Twenty-six of 77 (34%) Tdt+ patients assessable for response, entered complete remission (CR) vs 121 of 209 (58%) Tdt- cases (P < 0.001). CD7 was expressed in 1...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401067

    authors: Venditti A,Del Poeta G,Buccisano F,Tamburini A,Cox-Froncillo MC,Aronica G,Bruno A,Del Moro B,Epiceno AM,Battaglia A,Forte L,Postorino M,Cordero V,Santinelli S,Amadori S

    更新日期:1998-07-01 00:00:00

  • Acute lymphoblastic leukemia with a hypodiploid karyotype with less than 40 chromosomes: the basis for division into two subgroups.

    abstract::This paper describes seven patients with ALL and a hypodiploid karyotype with less than 40 chromosomes. A consideration of these and 15 previously published cases indicates that they may be divided into two groups depending on chromosome number, i.e., less than 30 and 30-39. The less than 30 group are younger and pred...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Callen DF,Raphael K,Michael PM,Garson OM

    更新日期:1989-10-01 00:00:00

  • Different isoforms of the B-cell mutator activation-induced cytidine deaminase are aberrantly expressed in BCR-ABL1-positive acute lymphoblastic leukemia patients.

    abstract::The main reason for the unfavorable clinical outcome of BCR-ABL1-positive acute lymphoblastic leukemia (ALL) is genetic instability. However, how normal B-cell precursors acquire the genetic changes that lead to transformation has not yet been completely defined. We investigated the expression of the activation-induce...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2009.197

    authors: Iacobucci I,Lonetti A,Messa F,Ferrari A,Cilloni D,Soverini S,Paoloni F,Arruga F,Ottaviani E,Chiaretti S,Messina M,Vignetti M,Papayannidis C,Vitale A,Pane F,Piccaluga PP,Paolini S,Berton G,Baruzzi A,Saglio G,Baccar

    更新日期:2010-01-01 00:00:00

  • Cellular resistance mechanisms with impact on the therapy of multiple myeloma.

    abstract::Multiple myeloma (MM) is characterized by bone marrow infiltration with abnormal plasma cells which synthesize monoclonal immunoglobulins (Ig) or Ig fragments. Regularly, MM cells exhibit a high intrinsic resistance to available chemotherapeutic strategies. A number of cellular alterations including the cellular membr...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:

    authors: Gieseler F,Nüssler V

    更新日期:1997-12-01 00:00:00

  • Analysis of the immunoglobulin heavy chain gene variable region of CD5-positive and -negative diffuse large B cell lymphoma.

    abstract::We analyzed nucleotide sequence and intraclonal diversity of the rearranged immunoglobulin heavy chain gene variable region (VH gene) of CD5+ and CD5- diffuse large B cell lymphoma (DLBCL) to clarify the cell origin of de novo CD5+ DLBCL. Ten cases of CD5+ DLBCL and 29 cases of CD5- DLBCL were analyzed. The frequencie...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402031

    authors: Nakamura N,Kuze T,Hashimoto Y,Hara Y,Hoshi S,Sasaki Y,Shirakawa A,Sato M,Abe M

    更新日期:2001-03-01 00:00:00

  • Effect of ubenimex on the proliferation and differentiation of U937 human histiocytic lymphoma cells.

    abstract::We investigated the effect of ubenimex on the growth and differentiation of U937 cells, a histiocytic lymphoma cell line. Ubenimex is a dipeptide ((2S,3R)-3-amino-2-hydroxy-4-phenylbutyryl-L-leucine) and an inhibitor of aminopeptidase B produced by Streptomyces olivoreticuli. Ubenimex inhibited the proliferation of U9...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Murata M,Kubota Y,Tanaka T,Iida-Tanaka K,Takahara J,Irino S

    更新日期:1994-12-01 00:00:00

  • Spliceosome and other novel mutations in chronic lymphocytic leukemia and myeloid malignancies.

    abstract::Spliceosome mutations represent a new generation of acquired genetic alterations that affect both myeloid and lymphoid malignancies. A substantial proportion of patients with myelodysplastic syndromes (MDSs) or chronic lymphocytic leukemia (CLL) harbor such mutations, which are often missense in type. Genotype-phenoty...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/leu.2012.86

    authors: Damm F,Nguyen-Khac F,Fontenay M,Bernard OA

    更新日期:2012-09-01 00:00:00

  • Impact of PTEN abnormalities on outcome in pediatric patients with T-cell acute lymphoblastic leukemia treated on the MRC UKALL2003 trial.

    abstract::PTEN gene inactivation by mutation or deletion is common in pediatric T-cell acute lymphoblastic leukemia (T-ALL), but the impact on outcome is unclear, particularly in patients with NOTCH1/FBXW7 mutations. We screened samples from 145 patients treated on the MRC UKALL2003 trial for PTEN mutations using heteroduplex a...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2015.206

    authors: Jenkinson S,Kirkwood AA,Goulden N,Vora A,Linch DC,Gale RE

    更新日期:2016-01-01 00:00:00

  • Current recommendations for positive controls in RT-PCR assays.

    abstract::The choice of adequate controls for reverse transcriptase (RT-) PCR analysis has been the focus of a debate pursued in Leukemia over the past 3 years. Twenty-six authors from 15 different centers contributed to the Debate, and the points presented have been carefully evaluated. This survey reviews the issues discussed...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/sj.leu.2402133

    authors: Lion T

    更新日期:2001-07-01 00:00:00

  • Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with

    abstract::To compare the antileukemic efficacy of idarubicin and mitoxantrone in elderly patients with acute myeloid leukemia (AML) and to evaluate the feasibility of autologous transplantation using PBSC after consolidation in those with a good performance status, 160 patients (median age 69 years), with AML at diagnosis, 118 ...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1038/sj.leu.2401445

    authors: Archimbaud E,Jehn U,Thomas X,De Cataldo F,Fillet G,Belhabri A,Peaud PY,Martin C,Amadori S,Willemze R

    更新日期:1999-06-01 00:00:00

  • Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.

    abstract::Older adults with acute myeloid leukemia (AML) who are not fit for standard chemotherapy historically have poor outcomes. Approximately 12-15% of older patients with AML harbor isocitrate dehydrogenase 2 (IDH2) gene mutations. Enasidenib is an oral inhibitor of mutant IDH2 proteins. Among 39 patients with newly diagno...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究

    doi:10.1038/s41375-019-0472-2

    authors: Pollyea DA,Tallman MS,de Botton S,Kantarjian HM,Collins R,Stein AS,Frattini MG,Xu Q,Tosolini A,See WL,MacBeth KJ,Agresta SV,Attar EC,DiNardo CD,Stein EM

    更新日期:2019-11-01 00:00:00

  • Lack of reciprocal translocation in BCR-ABL positive Ph-negative chronic myeloid leukaemia.

    abstract::We used fluorescence in situ hybridization (FISH) to metaphase chromosomes with BCR and ABL cosmid probes in conjunction with the polymerase chain reaction (PCR) to study the mechanism by which the ABL proto-oncogene is inserted into a morphologically normal chromosome 22 in patients with Ph-negative chronic myeloid l...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Lazaridou A,Chase A,Melo J,Garicochea B,Diamond J,Goldman J

    更新日期:1994-03-01 00:00:00

  • Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas.

    abstract::Viral infection induces potent cellular immunity and activated intracellular signaling, which may dictate the driver events involved in immune escape and clonal selection of virus-associated cancers, including Epstein-Barr virus (EBV)-positive lymphomas. Here, we thoroughly interrogated PD-L1/PD-L2-involving somatic a...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-019-0380-5

    authors: Kataoka K,Miyoshi H,Sakata S,Dobashi A,Couronné L,Kogure Y,Sato Y,Nishida K,Gion Y,Shiraishi Y,Tanaka H,Chiba K,Watatani Y,Kakiuchi N,Shiozawa Y,Yoshizato T,Yoshida K,Makishima H,Sanada M,Onozawa M,Teshima T,Yos

    更新日期:2019-07-01 00:00:00

  • Molecular cloning of a 5' segment of the genomic phl gene defines a new breakpoint cluster region (bcr2) in Philadelphia-positive acute leukemias.

    abstract::Molecular rearrangements of Ph1 chromosome, the hallmark of CML, are clustered in a 5.8-kb DNA segment, the so-called breakpoint cluster region (bcr) of the phl gene that is localized to chromosome 22q11. In Ph1-positive (Ph1+) ALLs, the rearrangements have been shown to involve either the 5.8-kb bcr (called bcr+) or ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Chen SJ,Chen Z,Grausz JD,Hillion J,d'Auriol L,Flandrin G,Larsen CJ,Berger R

    更新日期:1988-10-01 00:00:00

  • Resistance to RadLV-induced leukemia: non-participation of splenic natural killer cells.

    abstract::The phenotypic expression of genetically determined resistance to radiation leukemia virus (RadLV)-induced leukemia in mice has been shown to reside in the bone marrow. Because the bone marrow contains precursors of natural killer (NK) cells, known to play a role in retrovirally induced infections, and because these c...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: St-Pierre Y,Hugo P,Lemieux S,Lussier G,Potworowski EF

    更新日期:1988-08-01 00:00:00

  • Induction of microRNAs, mir-155, mir-222, mir-424 and mir-503, promotes monocytic differentiation through combinatorial regulation.

    abstract::Acute myeloid leukemia (AML) involves a block in terminal differentiation of the myeloid lineage and uncontrolled proliferation of a progenitor state. Using phorbol myristate acetate (PMA), it is possible to overcome this block in THP-1 cells (an M5-AML containing the MLL-MLLT3 fusion), resulting in differentiation to...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2009.246

    authors: Forrest AR,Kanamori-Katayama M,Tomaru Y,Lassmann T,Ninomiya N,Takahashi Y,de Hoon MJ,Kubosaki A,Kaiho A,Suzuki M,Yasuda J,Kawai J,Hayashizaki Y,Hume DA,Suzuki H

    更新日期:2010-02-01 00:00:00

  • Megakaryocytic growth factors: is there a new approach for management of thrombocytopenia in patients with malignancies?

    abstract::C-mpl ligand acts primarily as a lineage-specific hematopoietic growth factor by promoting proliferation of megakaryocyte precursors and their differentiation into megakaryocytes and platelets. In addition to the ability of c-mpl ligand to support megakaryocytic development from CD34+ precursor cells, several lines of...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:

    authors: Hofmann WK,Ottmann OG,Hoelzer D

    更新日期:1999-01-01 00:00:00

  • Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients.

    abstract::We previously identified autoantibodies to the endocytic-associated protein Huntingtin-interacting protein 1-related (HIP1R) in diffuse large B-cell lymphoma (DLBCL) patients. HIP1R regulates internalization of cell surface receptors via endocytosis, a process relevant to many therapeutic strategies including CD20 tar...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2013.224

    authors: Wong KK,Gascoyne DM,Brown PJ,Soilleux EJ,Snell C,Chen H,Lyne L,Lawrie CH,Gascoyne RD,Pedersen LM,Møller MB,Pulford K,Murphy D,Green TM,Banham AH

    更新日期:2014-02-01 00:00:00

  • Effect of the protein kinase C activating agent bryostatin 1 on the clonogenic response of leukemic blast progenitors to recombinant granulocyte-macrophage colony-stimulating factor.

    abstract::Bryostatin 1 is a macrocyclic lactone activator of protein kinase C which has displayed promising antileukemic potential in pre-clinical studies. We have assessed the effect of bryostatin 1 on the in vitro clonogenic response of leukemic myeloblasts obtained from 12 patients with acute non-lymphocytic leukemia to reco...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Grant S,Pettit GR,Howe C,McCrady C

    更新日期:1991-05-01 00:00:00

  • Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia.

    abstract::Adults with acute lymphoblastic leukemia (ALL) do worse than children. From 7/2008 to 12/2014, Nordic and Baltic centers treated 1509 consecutive patients aged 1-45 years with Philadelphia chromosome-negative ALL according to the NOPHO ALL2008 without cranial irradiation. Overall, 1022 patients were of age 1-9 years (...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2017.265

    authors: Toft N,Birgens H,Abrahamsson J,Griškevičius L,Hallböök H,Heyman M,Klausen TW,Jónsson ÓG,Palk K,Pruunsild K,Quist-Paulsen P,Vaitkeviciene G,Vettenranta K,Åsberg A,Frandsen TL,Marquart HV,Madsen HO,Norén-Nyström U,Schmi

    更新日期:2018-03-01 00:00:00

  • Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System.

    abstract::Allogeneic hematopoietic stem cell transplantation (allo-SCT) represents the only curative treatment for patients with myelodysplastic syndrome (MDS), but involves non-negligible morbidity and mortality. Crucial questions in clinical decision-making include the definition of optimal timing of the procedure and the ben...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2017.88

    authors: Della Porta MG,Jackson CH,Alessandrino EP,Rossi M,Bacigalupo A,van Lint MT,Bernardi M,Allione B,Bosi A,Guidi S,Santini V,Malcovati L,Ubezio M,Milanesi C,Todisco E,Voso MT,Musto P,Onida F,Iori AP,Cerretti R,Grillo

    更新日期:2017-11-01 00:00:00

  • Interleukin-4-mediated inhibition of C-Fos mRNA expression: role of the lipoxygenase directed pathway.

    abstract::Interleukin-4 inhibits several monocyte functions like A23187-induced expression of cytokines and c-fos and c-jun proto-oncogene mRNA expression. In an attempt to elucidate the mechanism by which this inhibitive effect is mediated, we compared the effect of IL-4 on A23187-induced c-fos and c-jun mRNA expression in con...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Dokter WH,Sierdsema SJ,Esselink MT,Halie MR,Vellenga E

    更新日期:1994-07-01 00:00:00